ArticlePain and therapy2023
Remimazolam Compared to Propofol During Hysteroscopy: A Safety and Efficacy Analysis.
Article in Pain and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- RemimazolamPeerJ · 2026Pooled it
- Efficacy and safety of remimazolam for sedation during gynaecologic procedures: a systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- Efficacy and Safety of Remimazolam in Short Endoscopic Procedures: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Safety and efficacy of remimazolam versus propofol sedation in gynecological procedures: a meta-analysis of East Asian randomized trials.Frontiers in medicine · 2025Pooled it
- Repeated remimazolam sedation for interstitial brachytherapy in cervical cancer: a randomized controlled trial.Annals of medicine · 2026Trial
- Effect of Different Doses of Esketamine on the Propofol Effect-Site Concentration Required to Suppress Cervical Dilation-Associated Movement During Hysteroscopy: A Prospective, Randomised, Controlled, Parallel-Group Dose-Response Trial.Drug design, development and therapy · 2026Trial
- Remimazolam tosylate vs. propofol: effects on anesthetic efficacy and renal function in living donor kidney transplantation.BMC anesthesiology · 2025Trial
- Determining the 90% Effective Dose of Remimazolam to Prevent Physical Movement in Surgical Abortions: A Biased-Coin Up-and-Down Sequential Allocation Trial.Drug design, development and therapy · 2025Trial
- Effect of Remimazolam vs Midazolam on Early Postoperative Cognitive Recovery in Elderly Patients Undergoing Dental Extraction: A Prospective Randomized Controlled Study.Drug design, development and therapy · 2024Trial
- Comparing Remimazolam and Propofol for Postoperative Anesthesia Satisfaction in Outpatient Gynecological Surgery: A Randomized Clinical Trial.Drug design, development and therapy · 2024Trial
- Clinical Application Study of Different Doses of Remimazolam Combined With Sevoflurane in Pediatric Adenoidectomy.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-facialeTrial
- Review of clinical advances in the procedural sedation application of remimazolam.Frontiers in pharmacology · 2026Review
- Article
- Remimazolam in anesthesia and sedation: A narrative review.Journal of anesthesia and translational medicine · 2025Review
- Remimazolam and Its Place in the Current Landscape of Procedural Sedation and General Anesthesia.Journal of clinical medicine · 2024Review
- Clinical study on the safety and efficacy of remimazolam in hysteroscopic surgery under general anesthesia in elderly patients.Frontiers in medicine · 2024Article
- The efficacy and safety of remimazolam besylate, ciprofol, and propofol during hysteroscopy.Frontiers in pharmacology · 2024Article
- Efficacy and safety of remimazolam besilate for sedation in outpatients undergoing impacted third molar extraction: a prospective exploratory study.BMC oral health · 2023Article
- Modified Dixon sequential method to determine the effective dose of alfentanil compounded with propofol for day-case hysteroscopy.Therapeutic advances in drug safety · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPropofol is the main drug used to induce sedation for endoscopic procedures, and few drugs had shaken its dominant clinical use for a decade until the development of remimazolam. Remimazolam has been demonstrated to perform well in post-marketing studies on sedation for colonoscopy or other procedures requiring short periods of sedation. This study aimed to establish whether remimazolam was effective and safe for inducing sedation for hysteroscopy.
methodsOne hundred patients who were scheduled to undergo hysteroscopy were randomly assigned to receive induction with remimazolam or propofol. A dose of 0.25 mg/kg remimazolam was administered. Propofol was started at 2-2.5 mg/kg. Before remimazolam or propofol induction, 1 μg/kg fentanyl was infused. Hemodynamic parameters, vital signs, and bispectral index (BIS) values were measured and adverse events recorded to evaluate safety. We comprehensively evaluated the efficacy and safety of the two drugs by the success rate of induction, fluctuation of vital signs, depth of anesthesia, adverse reactions, recovery time, and other indicators.
resultsInformation on 83 patients was successfully recorded and carefully documented. The success rate of sedation in the remimazolam group (group R) was 93%, which was lower than for the propofol group (group P) (100%), but there was no statistically significant difference between the two groups. The incidence of adverse reactions in group R (7.5%) was significantly lower than that in group P (67.4%), and the results were statistically significant (P < 0.01). The fluctuation of vital signs in group P was more severe after induction, especially in patients with cardiovascular diseases.
conclusionsRemimazolam avoids the injection pain produced by propofol sedation, has a better pre-sedation experience, had the advantage of stable hemodynamics after injection compared to propofol, and a lower respiratory depression rate in the study patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.